Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 11.94
(-0.5%)
AUD 11.94
(-0.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 88.17 Million AUD | 12.59% |
| 2023 | 78.32 Million AUD | 19.17% |
| 2022 | 65.72 Million AUD | 36.99% |
| 2021 | 47.97 Million AUD | 47.32% |
| 2020 | 32.56 Million AUD | 4.89% |
| 2019 | 31.04 Million AUD | 21.82% |
| 2018 | 25.48 Million AUD | 52.01% |
| 2017 | 16.76 Million AUD | 145.81% |
| 2016 | 6.82 Million AUD | 105.58% |
| 2015 | 3.31 Million AUD | 24.58% |
| 2014 | 2.66 Million AUD | 71.48% |
| 2013 | 1.55 Million AUD | 114.86% |
| 2012 | 722.8 Thousand AUD | -30.57% |
| 2011 | 1.04 Million AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | -100.0% |
| 2007 | 283.3 Thousand AUD | -62.47% |
| 2006 | 754.84 Thousand AUD | 505.71% |
| 2005 | 124.62 Thousand AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 88.17 Million AUD | 12.59% |
| 2024 Q2 | 32.25 Million AUD | 0.0% |
| 2024 Q4 | 55.37 Million AUD | 0.0% |
| 2023 Q4 | 48.96 Million AUD | 0.0% |
| 2023 FY | 78.32 Million AUD | 19.17% |
| 2023 Q2 | 29.35 Million AUD | 0.0% |
| 2022 FY | 65.72 Million AUD | 36.99% |
| 2022 Q2 | 24.63 Million AUD | 0.0% |
| 2022 Q4 | 41.09 Million AUD | 0.0% |
| 2021 FY | 47.97 Million AUD | 47.32% |
| 2021 Q2 | 15.74 Million AUD | 0.0% |
| 2021 Q4 | 32.23 Million AUD | 0.0% |
| 2020 Q4 | 22.59 Million AUD | 0.0% |
| 2020 Q2 | 9.97 Million AUD | 0.0% |
| 2020 FY | 32.56 Million AUD | 4.89% |
| 2019 Q2 | 8.98 Million AUD | 0.0% |
| 2019 Q4 | 22.06 Million AUD | 0.0% |
| 2019 FY | 31.04 Million AUD | 21.82% |
| 2018 FY | 25.48 Million AUD | 52.01% |
| 2018 Q4 | 18.41 Million AUD | 0.0% |
| 2018 Q2 | 7.06 Million AUD | 0.0% |
| 2017 Q2 | 6.88 Million AUD | 0.0% |
| 2017 FY | 16.76 Million AUD | 145.81% |
| 2017 Q4 | 9.87 Million AUD | 0.0% |
| 2016 Q4 | 5.19 Million AUD | 0.0% |
| 2016 FY | 6.82 Million AUD | 105.58% |
| 2016 Q2 | 1.63 Million AUD | 0.0% |
| 2015 FY | 3.31 Million AUD | 24.58% |
| 2015 Q4 | 2.24 Million AUD | 0.0% |
| 2015 Q2 | 1.07 Million AUD | 0.0% |
| 2014 Q2 | 846.5 Thousand AUD | 0.0% |
| 2014 Q4 | 1.81 Million AUD | 0.0% |
| 2014 FY | 2.66 Million AUD | 71.48% |
| 2013 Q3 | 388.24 Thousand AUD | -60.74% |
| 2013 Q4 | 1.5 Million AUD | 286.61% |
| 2013 FY | 1.55 Million AUD | 114.86% |
| 2013 Q1 | 180.7 Thousand AUD | 0.0% |
| 2013 Q2 | 989 Thousand AUD | 447.32% |
| 2012 Q2 | 180.7 Thousand AUD | -30.57% |
| 2012 FY | 722.8 Thousand AUD | -30.57% |
| 2012 Q4 | 180.7 Thousand AUD | 0.0% |
| 2012 Q3 | 180.7 Thousand AUD | 0.0% |
| 2012 Q1 | 260.25 Thousand AUD | 0.0% |
| 2011 Q1 | - AUD | 0.0% |
| 2011 Q2 | 260.25 Thousand AUD | 0.0% |
| 2011 FY | 1.04 Million AUD | 0.0% |
| 2011 Q3 | 260.25 Thousand AUD | 0.0% |
| 2011 Q4 | 260.25 Thousand AUD | 0.0% |
| 2010 Q2 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2010 Q1 | - AUD | 0.0% |
| 2010 Q3 | - AUD | 0.0% |
| 2009 Q1 | - AUD | 0.0% |
| 2009 Q3 | - AUD | 0.0% |
| 2009 Q2 | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 Q2 | - AUD | -100.0% |
| 2008 Q1 | 70.82 Thousand AUD | 0.0% |
| 2008 FY | - AUD | -100.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 Q3 | - AUD | 0.0% |
| 2007 Q3 | 70.82 Thousand AUD | 0.0% |
| 2007 Q2 | 70.82 Thousand AUD | -62.47% |
| 2007 FY | 283.3 Thousand AUD | -62.47% |
| 2007 Q1 | 188.71 Thousand AUD | 0.0% |
| 2007 Q4 | 70.82 Thousand AUD | 0.0% |
| 2006 FY | 754.84 Thousand AUD | 505.71% |
| 2006 Q3 | 188.71 Thousand AUD | 0.0% |
| 2006 Q1 | 31.15 Thousand AUD | 0.0% |
| 2006 Q4 | 188.71 Thousand AUD | 0.0% |
| 2006 Q2 | 188.71 Thousand AUD | 505.72% |
| 2005 Q2 | 31.15 Thousand AUD | 0.0% |
| 2005 Q4 | 31.15 Thousand AUD | 0.0% |
| 2005 Q3 | 31.15 Thousand AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2005 FY | 124.62 Thousand AUD | 0.0% |
| 2004 Q3 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2004 Q2 | - AUD | 0.0% |
| 2003 Q1 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 Q2 | - AUD | 0.0% |
| 2002 Q3 | - AUD | 0.0% |
| 2002 Q2 | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 66.44 Million AUD | -32.712% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -92766.193% |
| Biome Australia Limited | 13 Million AUD | -577.831% |
| Patrys Limited | 1.39 Million AUD | -6224.821% |
| Orthocell Limited | 5.31 Million AUD | -1558.929% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | 2.4 Million AUD | -3573.674% |
| PYC Therapeutics Limited | 22.05 Million AUD | -299.733% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -1082.386% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -2275.26% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -9783.876% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -3707.941% |
| CSL Limited | 22.41 Billion AUD | 99.607% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -518595.929% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -481222.642% |
| Starpharma Holdings Limited | 8.28 Million AUD | -963.799% |
| Nanollose Limited | 12.5 Thousand AUD | -705270.034% |
| Memphasys Limited | 60 Thousand AUD | -146863.847% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -7173.902% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -1880.315% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -14551.94% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -6945.387% |
| Race Oncology Limited | 4 Million AUD | -2102.547% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 82.246% |
| Dimerix Limited | 583.47 Thousand AUD | -15012.533% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | -2415.268% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | -666.324% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -2093.88% |
| BTC Health Limited | 16.36 Thousand AUD | -538887.213% |
| Acrux Limited | 5.09 Million AUD | -1632.043% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 61.98% |
| Biotron Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -57820.591% |
| AdAlta Limited | 1.73 Million AUD | -4974.14% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -29368.602% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -19052.668% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -133909.587% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -18520.657% |
| Actinogen Medical Limited | 9.93 Million AUD | -787.865% |
| Immuron Limited | 4.9 Million AUD | -1698.506% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -3294.167% |